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Abstract
Background: To investigate the effect of HBV on the proliferative ability of host cells and explore the potential
mechanism.
Methods: MTT, colony formation assay and tumourigenicity in nude mice were performed to investigate the effect
of HBV on the proliferative capability of host cells. In order to explore the potential mechanism, cell cycle and
apoptosis were analysed. The cell cycle genes controlling the G1/S phase transition were detected by
immunohistochemistry, westernblot and RT-PCR.
Results: HepG2.2.15 cells showed decreased proliferation ability compared to HepG2 cells. G1 phase arrest was the
main cause but was not associated with apoptosis. p53, p21 and total retinoblastoma (Rb) were determined to be
up-regulated, whereas cyclinE was down-regulated at both the protein and mRNA levels in HepG2.2.15 cells. The
phosphorylated Rb in HepG2.2.15 cells was decreased.
Conclusions: Our results suggested that HBV inhibited the capability of proliferation of HepG2.2.15 cells by
regulating cell cycle genes expression and inducing G1 arrest.
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Background
Epidemiological and virological investigations have
shown that hepatitis B virus (HBV) infection is the main
cause of hepatocellular carcinoma (HCC) and is present
in approximately 80% of HCC patients [1-4]. Although
considerable studies have been done, the precise
mechanism remains unclear.
By now, HBV genome integration, gene mutation,
gene deletion and diverse viral factors have been proved
to be implicated in HBV-related HCC [5-8]. However,
little is known about the impacts of the complete HBV
genome or HBV replication on host cells.
The HepG2.2.15 cell line was established by transfect-
ing the HBV genome into HepG2 cells [9]. It supports
stable HBV replication and protein expression, as well
as the production of virus particles. HepG2.2.15 is a
widely used cell line in the study of the life cycle of
HBV and antiviral research [10-12]. It is also an ideal
model for investigating host-virus interaction [13,14].
Our previous study has found that HepG2.2.15 cell line
demonstrated distinct biological features compared with
parental HepG2. The comparative analysis between
HepG2.2.15 and HepG2 can help us to understand host-
virus interaction.
This study focused on the cell cycle control and
further investigated how HBV influenced the ability of
proliferation in HepG2.2.15 cells.
Materials and methods
Cell culture
The HepG2.2.15 cell line is a HepG2 cell line trans-
fected with a plasmid containing two head-to-tail dimers
of the HBV genome (GenBank accession: U95551.1).
Cells were cultured in Dulbecco’s modified Eagle med-
ium (DMEM, Hyclone, Logan, UT, USA) supplemented
with 10% FBS (Invitrogen, Carlsbad, CA, USA), 100 μg
ml
-1 streptomycin and 100 IU ml
-1 penicillin at 37°C in
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-1 G418 (Invitrogen) was
needed in HepG2.2.15 cells.
Identification of HBV replication in HepG2.2.15 cells
After 48 hours of seeding, the culture medium of
HepG2.2.15 cells was collected and assayed for extracel-
lular HBV DNA quantity by fluorescence quantitative
polymerase chain reaction (Q-PCR, PG BIOTECH,
Shenzhen, China). Hepatitis B surface antigen (HBsAg)
and Hepatitis B e antigen (HBeAg) in culture medium
were measured by ELISA (3V, Weifang, China) accord-
ing to the manufacturer’s instructions.
Electron microscopy
HepG2.2.15 and HepG2 cells were collected and washed
twice with PBS. After centrifugation, the cell pellet was
fixed with 2.5% glutaraldehyde for 12 h, post-fixed with
1% osmium tetroxide for 1 h, dehydrated in a graded
series of acetone and embedded in Epon 812. Sections
of 70-80 nm were cut, stained with uranyl acetate and
lead citrate, and viewed on a JEM 1220 transmission
electron microscope (JEOL, Tokyo, Japan).
MTT assay
Cells were seeded in 96-well plates at a density of 4 ×
10
3 cells per well and incubated in 200 μlD M E Mw i t h
serum for 1 to 5 days. MTT (5 mg ml
-1)w a sa d d e dt o
each well. After incubation at 37°C for 4 h, the superna-
tant containing MTT was removed and DMSO was
added to wells to suspend MTT-formazan crystals, and
viable cells were detected by measuring absorbance at
490 nm.
Colony formation assay
The cells were plated in 6-well plates at a density of 100
cells per well and cultured in regular culture medium.
After 2 weeks, cells were washed with PBS, fixed in 10%
methanol for 15 min, and stained with Giemsa. Colonies
which consisted of >50 cells were scored. The colony
formation rate was calculated as a percentage of total
seeded cells.
Tumourigenicity testing in vivo
In vivo experiments used 16 four-week-old female
nude mice (BALB/cASlac-nu) obtained from Shanghai
Laboratory Animal Center of Chinese Academy
Sciences. Mice were randomly divided into HepG2.2.15
and HepG2 group. 1 × 10
7 tumour cells in 0.3 ml PBS
were subcutaneously injected into the flank region of
nude mice. All nude mice were sacrificed on day 28.
Animal care and experimental procedures were
approved by the Committee for Ethics in Animal
Experimentation of Harbin Medical University, and
were conducted in accordance with the Guidelines for
Animal Experiments of the National Cancer Center of
China.
Cell cycle analysis
Cell cycle profiles were analysed using FACS. Briefly, 1
×1 0
6 cells were trypsinized, rinsed twice with PBS and
fixed with 70% cold ethanol at 4°C overnight. Fixed cells
were washed with PBS and stained with 200 μl of propi-
dium iodide (PI) for 30 min without light. The cell cycle
was analysed by a flow cytometry (BD, San Jose, CA,
USA).
Apoptosis assay by TUNEL
Apoptotic cells were detected by the terminal deoxynu-
cleotidyl transferase (TDT)- mediated deoxyuridine tri-
phosphate nick-end labelling (TUNEL) technique. The
cells seeded on coverslips were fixed by formaldehyde at
room temperature for 30 min and permeabilised with
0.1% Triton X-100 for 5 min. Apoptotic cells were
labelled using an in situ apoptosis detection kit (Roche,
Penzberg, Germany) and observed by fluorescence
microscopy.
Western blot analysis
The total protein extracted from cells were separated by
12% SDS-PAGE and transferred onto PVDF membranes.
The membranes were blocked by 5% dried non-fat milk
overnight, incubated with anti-p27 (Boster, Wuhan,
China), anti-p16, anti-p53, anti-cyclinD1 and anti-
cyclinE (Santa Cruz, CA, USA), anti-GAPDH and anti-
p21 (Calbiochem, Gibbstown, NJ, USA), anti-Rb and
anti-pRb (ser795) (SAB, Pearland, TX, USA) antibodies
in 1:500 dilution for 2 h at 37°C, washed and further
incubated with alkaline phosphatase (AP)-conjugated
secondary antibodies (Santa Cruz) for 1 h at room tem-
perature. Immunoreactive bands were detected using
western blue (Promega, Madison, WI, USA). GAPDH
was used as internal control.
Immunohistochemical staining
HepG2.2.15 and HepG2 cells were collected and centri-
fuged. The pellet of tumour cells were embedded in par-
affin and sections of 5 um were cut. The sections were
deparaffinised, blocked and incubated with anti-p53,
anti-p21, anti-p27, anti-p16, anti-cyclinD1, anti- cyclinE,
anti-Rb and anti-pRb (ser795) antibodies in 1:50 dilution
at 4°C overnight. Immunohistological staining was visua-
lized using the streptavidin-peroxidase kit (ZSGB Bio,
Beijing, China).
RT-PCR analysis
Total RNA was extracted from HepG2.2.15 and HepG2
cells using TRIzol (Invitrogen). First-strand cDNA was
synthesized using oligo (dT) -adaptor primer and AMV
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tions were performed using the primer pairs listed in
Table 1, and the GAPDH gene was used as an internal
control. Amplification products were resolved by 1.5%
agarose gel electrophoresis.
Statistical analysis
All data were presented as mean ± SD. The two groups
were compared with Student’s t test and Fisher’s exact.
A P < 0.05 was considered statistically significant.
Results
Identification of HBV replication in HepG2.2.15 cells
Q-PCR results showed that the average amount of HBV
DNA released from HepG2.2.15 cells at 48 h was (2.49
±0 . 3 6 )× 1 0
6 copies ml
-1. HBsAg and HBeAg were
strongly positive by ELISA. Taken together, these results
confirmed HBV expression in HepG2.2.15 cells.
Morphological features of HepG2.2.15 cells
HepG2.2.15 cells grew in multiple adherent layers in in
vitro culture (Figure 1A) and adhered to the wall of the
culture vessel within 24 h and by passage 1 to 2 on days
4-5. HepG2 cells grew in an adherent monolayer with
polygonal morphology (Figure 1A) and grew faster than
HepG2.2.15 cells where they adhered to the wall of the
culture vessel after 2 h and by passage 1 to 2 after 2
days.
Ultrastructural analysis of cells revealed that, com-
pared to HepG2 cell, the HepG2.2.15 cell body was rela-
tively larger, karyoplasmic ratio was decreased, cellular
surface projections became shortened or disappeared,
cellular organelles were porous and mitochondria were
enlarged (Figure 1Bi). Virus inclusions containing virus
particles were visible in the cytoplasm of HepG2.2.15
cells (ii). The body of HepG2 cells was relatively smaller.
Compact cytoplasm, cellular organs and many surface
projections were observed in HepG2 cells (iii).
Lower proliferation ability of HepG2.2.15 cells in vitro and
in vivo
T h eM T Ta s s a yp r o v e dt h a tt h eg r o w t hr a t eo f
HepG2.2.15 cells was significantly slower than that in
HepG2 cells on days 2-5 after seeding (P < 0.05) (Figure
2A). The colony formation rate was significantly lower
in HepG2.2.15 cells than in HepG2 cells (P < 0.01) (Fig-
ure 2B).
HepG2.2.15 cells formed tumours in 2 of 8 mice,
whereas HepG2 cells formed tumours in all eight mice.
The tumours caused by HepG2.2.15 cells could be
observed after 22 days, whereas the tumours from
HepG2 cells could be observed after 2 days. The tumour
formation rate of HepG2.2.15 cells was lower compared
with HepG2 cells (P < 0.05).
HBV induces cell cycle arrest in HepG2.2.15 cells
The percentage of cells in each phase of the cell cycle
was determined for HepG2.2.15 and HepG2 cells grown
in vitro (Table 2). The proportion of cells in G1 phase
increased, whereas cells in S phase decreased in
HepG2.2.15 compared to HepG2 cells (Figure 3A).
HepG2.2.15 cell cycle was arrested at the G1 phase.
Apoptosis was determined by TUNEL assay (Figure 3B).
The apoptotic rates were low and there was no signifi-
cant difference observed for HepG2.2.15 and HepG2 cell
line.
HBV regulates the expression of cell cycle genes in
HepG2.2.15 cells
To explore the mechanism of G1 phase arrest, the levels
of cell cycle regulator proteins controlling the G1/S
phase transition were analyzed by western blot (Figure
4B). We determined that p53, p21 and total Rb were
increased, while cyclinE and phosphorylated Rb were
decreased in HepG2.2.15 cells compared to those in
HepG2 cells. The levels of p16 and p27 showed no sig-
nificant difference between the two cell lines.
Table 1 Primer sequences for the genes used in RT-PCR analyses.
Gene Length of production (bp) Primer sequences
p53 638 Sense:5-TGTCCTGGGAGAGACCGGCG-3
Antisense:5-GTGGAGCCCCGGGACAAAGC-3
p21 156 Sense:5-GGACAGCAGAGGAAGAC-3
Antisense:5-GGCGTTTGGAGTGGTAGAAA-3
CCND1 480 Sense:5-AGCTCCTGTGCTGCGAAGTGG AAAC-3
Antisense:5-AGTGTTCAATGAAATCGTGCGGGGT-3
CCNE 586 Sense:5-CAGCACTTTCT TG AGCAACACCCTC-3
Antisense:5-TCTCTAT GTCGCACCACTGATACCC-3
RB1 232 Sense:5-CGGGAGTCGGGAGAGGACGG-3
Antisense:5-CGAGAGGCAGGTCCTCCGGG-3
GAPDH 452 Sense:5-ACC ACAGTCCATGCCATCAC-3 Antisense:5-TCCACCACCCTGTTGCTGTA-3
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Page 3 of 8Figure 1 Morphological features. (A) Morphological feature under inverted microscope. The magnification is 400×. HepG2.2.15 cell line grew in
multilayer and adherence. HepG2 cell line grew in monolayer and adherence. (B) Ultrastructural characteristic. Bar, 500 nm. (i) HepG2.2.15 cell
(×3000). (ii) Virus inclusion in HepG2.2.15 cell (×15 k). Bottom left is further magnification (×30 k). (iii) HepG2 cell (×6000).
Figure 2 Detection of cellular growth in vitro. (A) MTT assay. HepG2.2.15 cells grew slower than HepG2 cells. (B) Colony formation assay. The
average number of colonies of HepG2.2.15 cells was 17.7 ± 5.0 and that of HepG2 cells was 56.3 ± 7.6.
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tern blot (Figure 4A). CyclinD1 was increased in
HepG2.2.15 by western blot, but there was no significant
difference between the two cell lines by
immunohistochemistry.
To determine the point of regulation, the mRNA
levels of the altered proteins, including p53, p21,
cyclinD1, cyclinE and Rb, were detected by RT-PCR
(Figure 4C). We found that in HepG2.2.15 cells, expres-
sion of p53, p21, cyclinD1 and Rb was up-regulated and
expression of cyclinE was down-regulated. Taken
together, HBV affected host gene expression at both the
mRNA and protein levels.
Discussion
In this study, ultrastructural features suggested that
HepG2.2.15 cells showed decreased ability of prolifera-
tion compared to HepG2 cells, which was consistent
with in vivo and in vitro investigations. The result was
supported by other investigators[15,16].
We explored the possible mechanism of decreased
proliferation of HepG2.2.15 cells by investigating the
cell cycle and apoptosis. Our data indicated that
approximately 80% of HepG2.2.15 cells were arrested in
the G1 phase of replication but few apoptotic cells were
observed in in vitro culture. So the reason for slower
proliferation of HepG2.2.15 cells was cell cycle arrest
and not due to an increase in apoptosis.
HBV DNA was determined to be present at (2.49 ±
0.36) ×10
6 copies ml
-1 in the culture medium of
HepG2.2.15 cells and such a high load of HBV replica-
tion may be the cause of cell cycle arrest [17] reported
that HBV replication was cell-cycle dependent and there
was a negative correlation between cell proliferation and
the presence of episomal HBV DNA in hepatocytes.
Table 2 Cell cycle distribution of HepG2.2.15 and HepG2
cells.
Cell line Percentage of each cell cycle phase (%)
G1 S G2/M
HepG2.2.15 79.869 ± 6.408* 17.483 ± 5.176* 2.647 ± 2.659
HepG2 57.256 ± 10.880 34.251 ± 7.563 8.494 ± 3.420
Compared with HepG2, *P < 0.05
Figure 3 Cell cycle and apoptosis assay. (A) Cell cycle analysis by FACS. The majority of HepG2.2.15 cells arrested in G1 phase. (B) Cell
apoptosis assay by TUNEL. Little cells were apoptotic.
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Page 5 of 8Figure 4 Protein and mRNA assays for the detection of p53, p21, p27, p16, cyclinD1, cyclinE, Rb and pRb. (A) Immunohistochemistry
assay (400×). Bar, 50 μm. All proteins were located in nuclei and a positive result was brown nuclear staining. (B) Western blot analysis. (C) Semi-
quantitative RT-PCR analysis. (D) The relative expression level of each protein was represented as the fold ratio. Compared with HepG2 cells. *p <
0.05, **p < 0.01.
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Page 6 of 8HBV replication was active in quiescent hepatocytes but
slowed when hepatocytes started to divide [18]. The
expression of the complete HBV genome could signifi-
cantly decrease the proliferation rate by affecting cell
cycle control [19]. HBV can affect gene expression in
host cells [10] detected differentially expressed genes in
HepG2.2.15 and HepG2 cells by the use of a Human
Whole Genome Bioarray and found that 2978 genes,
including 53 cell- cycle related genes were up- or down-
regulated by at least two-fold. Some investigators
detected the proteome changes between HepG2.2.15
and HepG2 cell line, and determined that HBV induced
protein alterations in diverse cellular functional cate-
gories in host cell [14,20].
Did HBV induce G1 phase arrest by regulating the
expression of related genes? We examined the genes
controlling the G1/S phase transition. In HepG2.2.15
cells, the p21, which can negatively regulate the cell
cycle, was up-regulated markedly, whereas the cyclinE,
which typically positively regulate the cycle, was down-
regulated. Though cyclinD1 was increased in
HepG2.2.15 cells, phosphorylated Rb was reduced and
the cell cycle was arrested at G1 phase at last. The
change in p21 level was most significant among the
detected factors and can protect cells against apoptosis
by arresting cell cycle progression in the G1 phase to
repair [21]. Thus, the upregulation of p21 may be
important for the inhibition of HepG2.2.15 cell prolif-
eration. p53 was also increased in HepG2.2.15 cells,
which can induce the expression of p21 down-stream
[22]. It has been reported that p21 and p53 protein
were up-regulated in HepG2.2.15 cells, which was partly
consistent with our result [16]. The upregulation of p21
may also be relevant to HBx. HBx increases the expres-
sion of p21 in the presence of p53 and represses p21
when p53 is absent [23].
Additionally, increasing evidence has indicated that
the severity, clinical outcome, response to treatment and
prognosis of liver diseases are correlated with viral geno-
types but not all HBV genotypes are associated with
HCC [24-26]. For example, genotype C of HBV is more
likely to cause serious liver diseases [27,28]. China has a
large population of chronic HBV infection and the
majority are of genotype C. Moreover, 55% of liver can-
cer cases occur in China [29] and India also has many
chronic HBV infectious patients, but most are genotype
Aa n dDv i r u s e s .H o w e v e r ,t h ei n c i d e n c eo fH C Ci s
much lower in India than China [30]. The HBV geno-
type in HepG2.2.15 cells belongs to the D3 subgenotype.
At present, there is no report about the effects of HBV
D3 on host cells but epidemiological data suggest that
HBV subgenotype D3 may not be associated with HCC
[31]. Therefore, the alteration of proliferation ability in
HepG2.2.15 might be genotype D3 specific.
Conclusions
In conclusion, HepG2.2.15 cells showed decreased pro-
liferation ability compared to its parental HepG2 cells.
The possible mechanism was that HBV induced cell
cycle arrest by regulating the expression of the genes
related to G1/S transition. These results shed new light
on the interaction between HBV and host cell. Addi-
tionally, the results were good for understanding the
characteristics of HepG2.2.15 cells and selecting appro-
priate cell lines for research.
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